Comera Life Sciences Announces Expansion of Patent Portfolio Underlying Core Excipient Technology

Comera Life Sciences Holdings, Inc. recently announced the expansion of its patent portfolio with one new patent granted in South Korea and two Notices of Allowance in the US and Japan covering expansion of claims and exclusive rights pertaining to certain excipients in its proprietary SQore platform.

Comera is developing excipients designed to make subcutaneous (SQ) delivery of monoclonal antibodies possible. Many biologic therapies are delivered by intravenous (IV) infusion because the solutions exhibit high viscosity at elevated concentrations, preventing the concentrated drug’s manufacture and injection at volumes needed for SQ administration. Comera’s proprietary SQore platform is designed to decrease the viscosity of biologics, such as monoclonal antibodies, when used in high-concentration formulations.

The recent developments consist of the following:

  • Notice of Allowance from the US Patent and Trademark Office for expansion of core viscosity reduction patent claims toward antibody formulations and processing improvements with new excipient 1,3-dimethyluracil.
  • Issuance of South Korean Patent No. 2493469, which provides Comera exclusive rights pertaining to excipients hordenine, tryptamine, and trigonelline, with or without caffeine, in its SQore platform as viscosity-lowering agents.
  • Notice of Allowance from Japan’s Patent Office for Japanese Patent Application No. 2020-546123, titled Excipient compounds for protein formulations, for hordenine as viscosity-reducing excipient.

These developments reflect the growth of Comera’s intellectual property protection of its SQore platform to make improved formulations of biologics.

“This patent and two Notices of Allowance strengthen Comera’s robust, global patent portfolio with both expansion of claims to our core SQore platform and also geographic expansion outside of the US,” said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. “In conjunction with our existing patents, we believe this expanded intellectual property portfolio will provide value for our existing and future partners by increasing the potential commercial market and lifecycle extension opportunities with our SQore platform.”

Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from IV to SQ forms. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen. For more information, visit